H.C. Wainwright cuts EDAP stock price target to $14

Published 16/05/2025, 12:34
H.C. Wainwright cuts EDAP stock price target to $14

On Friday, H.C. Wainwright analyst Swayampakula Ramakanth revised the price target for EDAP TMS S.A. (NASDAQ:EDAP) to $14.00 from the previous $19.00, while retaining a Buy rating on the stock. The adjustment follows EDAP’s disclosure of its first-quarter financial results for 2025 and a corporate update on May 15. The stock, currently trading at $1.76, has experienced significant pressure, declining 74% over the past year. InvestingPro analysis indicates the company is currently undervalued, with 6 additional ProTips available for subscribers.

EDAP’s management is actively working to expand its core Focal One business. The company has been enhancing the Focal One technology platform, launching an alpha version for endometriosis treatment, and witnessing ongoing growth in equipment placements. At the 2025 annual meeting of the American Urological Association, EDAP unveiled the Focal One I Robotic HIFU system, which is compatible with various imaging systems and can integrate multiple data sets. With a market capitalization of $65.81 million and annual revenue of $67.91 million, the company maintains a healthy gross margin of 41.21%.

The company’s recent CE Mark certification has facilitated the controlled market introduction of Focal One for deep infiltrating endometriosis treatment in select European treatment centers. This initial launch is intended to gather clinical data in preparation for a wider release in regions recognizing the CE Mark. Insights from this phase are expected to inform the design of a randomized control Phase 3 study for U.S. marketing approval. While InvestingPro data shows the company is currently burning through cash, it maintains more cash than debt on its balance sheet, providing financial flexibility for these expansion initiatives.

In light of the company’s shift away from non-core businesses, H.C. Wainwright has adjusted its revenue projections for EDAP. The firm now forecasts total revenues to reach €212M by 2031, a reduction from the previous estimate of €260M. This recalibration has influenced the reduction of the 12-month price target for EDAP’s diluted American Depositary Shares (ADS) to $14, down from the earlier prediction of $19. For deeper insights into EDAP’s valuation and growth prospects, InvestingPro subscribers can access a comprehensive Pro Research Report, featuring detailed financial analysis and expert recommendations.

In other recent news, EDAP TMS S.A. reported its fourth-quarter 2024 earnings, showcasing a revenue increase of 3.6% year-over-year to €20.3 million, despite a net loss of €1.9 million, which improved from the previous year’s loss of €5 million. The company’s High-Intensity Focused Ultrasound (HIFU) revenue grew by 15.7% year-over-year, reaching €23.8 million, highlighting strong sales of its Focal One system. Piper Sandler adjusted its price target for EDAP TMS shares to $4.50, maintaining an Overweight rating, while Jefferies downgraded the stock from Buy to Hold, reducing the price target to $2.00 due to concerns over slower sales growth in the HIFU segment. H.C. Wainwright, however, reiterated a Buy rating with a $19.00 price target, expressing optimism about the company’s strategic focus on expanding its Focal One technology to new applications like pancreatic cancer and benign prostatic hyperplasia (BPH).

EDAP TMS is advancing its clinical trials, with active enrollment in the Phase 1/2 PULS study for pancreatic tumors and a similar study for BPH. The company also announced the positive results of the Focal Ablation versus Radical Prostatectomy (FARP) study, which demonstrated the effectiveness of focal ablation in treating localized prostate cancer. CEO Ryan Rhodes highlighted the growing recognition of Focal One as a necessary treatment option for prostate cancer, supported by favorable reimbursement changes from the Centers for Medicare and Medicaid Services. These developments, along with a strategic shift to focus more on HIFU, are expected to drive revenue growth for the company in 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.